论文部分内容阅读
目的观察晚期非小细胞肺癌(NSCLC)患者βⅢ-tubulin和Tau表达情况与含紫杉醇化疗敏感性的关系。方法 45例病理学确诊的晚期NSCLC患者,化疗前对肿瘤组织采用免疫组化法检测βⅢ-tubulin和Tau表达情况,对所有患者采用紫杉醇+铂类(顺铂或卡铂)方案化疗。观察βⅢ-tubulin和Tau表达情况与含紫杉醇化疗方案治疗非小细胞肺癌有效率之间的关系。结果βⅢ-tubulin和Tau表达与患者性别、年龄、病理类型、临床分期及既往化疗无关。βⅢ-tubulin阴性者紫杉醇化疗有效率明显高于βⅢ-tubulin阳性者(P<0.05);Tau阴性表达者应用紫杉醇化疗的有效率示高于阳性表达者(P<0.05);βⅢ-tubulin阴性及Tau表达阴性患者应用紫杉醇化疗有效率为83.3%。结论βⅢ-tubulin和Tau可作为晚期NSCLC患者应用紫杉醇联合方案的有效性的预测指标,为晚期NSCLC患者的个体化治疗提供参考。
Objective To observe the relationship between the expression of βⅢ-tubulin and Tau in patients with advanced non-small cell lung cancer (NSCLC) and the sensitivity of paclitaxel-containing chemotherapy. Methods Forty-five patients with advanced NSCLC diagnosed by pathology were examined for the expression of βⅢ-tubulin and Tau by immunohistochemistry before chemotherapy. All the patients were treated with paclitaxel + platinum (cisplatin or carboplatin) chemotherapy. To observe the relationship between the expression of βⅢ-tubulin and Tau and the efficiency of paclitaxel-containing chemotherapy in the treatment of non-small cell lung cancer. Results The expression of βⅢ-tubulin and Tau had no correlation with the gender, age, pathological type, clinical stage and previous chemotherapy. The effective rate of paclitaxel chemotherapy in patients with βⅢ-tubulin negative was significantly higher than those in βⅢ-tubulin positive (P <0.05); the effective rate of chemotherapy with paclitaxel was significantly higher in patients with Tau negative expression than those with positive expression of βⅢ-tubulin (P <0.05) Tau-negative patients with paclitaxel chemotherapy was 83.3%. Conclusion βⅢ-tubulin and Tau can be used as predictors of the efficacy of paclitaxel in patients with advanced NSCLC, and provide a reference for individualized treatment of patients with advanced NSCLC.